AMLX vs CUBE · rev $87.4M vs P/E 25, rev $1.07B
Amylyx Pharmaceuticals Inc (AMLX) versus CubeSmart (CUBE) — a side-by-side from cached financials, not a winner call.
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Latest reported AMLX revenue for 2024-12-31 was $87.4M. Net income was -$301.7M. Revenue was down 77.1% from 2023-12-31 to 2024-12-31. AMLX currently screens at market cap $561.6M.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
AMLX currently screens at market cap $561.6M. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Not investment advice. Open the AMLX and CUBE stock pages for the full models.
Not investment advice.